Title: Lentiviral Vectors, Related Reagents, and Methods of Use Thereof
Number: 20050251872
Filed: Sept. 5, 2003
Lead Inventor: James Bear, University of North Carolina Chapel Hill School of Medicine
The invention, the patent application's abstract states, "provides new lentiviral vectors, including lentiviral transfer plasmids and infectious lentiviral particles. Lentiviral vectors of the invention were designed to offer a number of desirable features including reduced size, convenient cloning sites (including multiple cloning sites and sites for particularly useful restriction enzymes), loxP sites, self-inactivating LTRs, etc."
The abstract states that "certain of the vectors are optimized for expression of reporter genes and/or for expression of siRNAs or shRNAs within eukaryotic cells. The invention also provides three- and four-plasmid lentiviral expression systems. In addition, the invention provides a variety of methods for using the vectors including gene silencing in cells and transgenic animals, and methods of treating disease."
Title: FcγRIIA-Specific Nucleic Acid Interference
Number: 20050250722
Filed: Nov. 15, 2004
Lead Inventor: Diana Beardsley, Yale University School of Medicine
"The … invention provides methods and compositions for attenuating expression of Fc.gamma.RIIA," the patent application's abstract states. "In general, the described methodology involves the use of RNAi constructs that are targeted to a FcγRIIA mRNA sequence."
Title: Gene Knock Down by Intracellular Expression of Aptamers
Number: 20050250106
Filed: April 23, 2004
Lead Inventor: David Epstein, Archemix
"Materials and methods are provided for target validation by gene knock-down with intracellularly expressed aptamers and siRNAs," the patent application's abstract states. "The aptamers produced by the materials and methods of the invention are useful in target validation for therapeutics development."
Â